• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Promise and challenges of traditional Chinese medicine, specifically , in liver cancer treatment.传统中医药,特别是在肝癌治疗方面的前景与挑战。
World J Gastroenterol. 2024 Oct 28;30(40):4380-4385. doi: 10.3748/wjg.v30.i40.4380.
2
From traditional Chinese medicine formulations to effective anticancer agents: Insights from Calculus bovis.从中药方剂到有效的抗癌药物:从牛 calculus 中获得的启示。
World J Gastroenterol. 2024 Sep 21;30(35):4011-4013. doi: 10.3748/wjg.v30.i35.4011.
3
Unveiling the anticancer effect of traditional Chinese herbal medicine.揭示传统中草药的抗癌作用。
World J Gastroenterol. 2024 Aug 14;30(30):3625-3627. doi: 10.3748/wjg.v30.i30.3625.
4
Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma.辅助中药治疗对肝癌患者长期生存的影响。
Phytomedicine. 2019 Sep;62:152930. doi: 10.1016/j.phymed.2019.152930. Epub 2019 May 11.
5
Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine.中西医结合治疗原发性肝癌临床实践指南。
J Integr Med. 2018 Jul;16(4):236-248. doi: 10.1016/j.joim.2018.05.002. Epub 2018 May 17.
6
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.中药治疗可能对接受铂类化疗或联合靶向治疗与化疗的 IV 期肺腺癌患者的预后有一定影响。
Integr Cancer Ther. 2011 Jun;10(2):127-37. doi: 10.1177/1534735410387599. Epub 2010 Dec 8.
7
The latest research progress: Active components of Traditional Chinese medicine as promising candidates for ovarian cancer therapy.最新研究进展:中药活性成分有望成为卵巢癌治疗的候选药物。
J Ethnopharmacol. 2025 Jan 30;337(Pt 1):118811. doi: 10.1016/j.jep.2024.118811. Epub 2024 Sep 7.
8
Traditional Chinese medicine in the treatment of breast cancer.中医治疗乳腺癌
Semin Oncol. 2002 Dec;29(6):563-74. doi: 10.1053/sonc.2002.50005.
9
The positive role of traditional Chinese medicine as an adjunctive therapy for cancer.中医作为癌症辅助治疗手段的积极作用。
Biosci Trends. 2021 Nov 21;15(5):283-298. doi: 10.5582/bst.2021.01318. Epub 2021 Aug 20.
10
[Survival time of advanced gastric cancer patients treated with integrated traditional Chinese and Western medicine therapy].[中西医结合治疗晚期胃癌患者的生存时间]
Zhong Xi Yi Jie He Xue Bao. 2010 Feb;8(2):116-20. doi: 10.3736/jcim20100204.

本文引用的文献

1
inhibits M2 tumor-associated macrophage polarization Wnt/β-catenin pathway modulation to suppress liver cancer.抑制 M2 肿瘤相关巨噬细胞极化,调节 Wnt/β-catenin 通路,抑制肝癌。
World J Gastroenterol. 2024 Aug 7;30(29):3511-3533. doi: 10.3748/wjg.v30.i29.3511.
2
Regulation of hepatocyte phospholipid peroxidation signaling by a Chinese patent medicine against psychological stress-induced liver injury.一种治疗心理应激性肝损伤的中药对肝细胞磷脂过氧化信号的调控。
Phytomedicine. 2024 Jul;129:155613. doi: 10.1016/j.phymed.2024.155613. Epub 2024 Apr 16.
3
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
4
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
5
Pien Tze Huang Inhibits Proliferation of Colorectal Cancer Cells through Suppressing PNO1 Expression and Activating p53/p21 Signaling Pathway.片仔癀通过抑制 PNO1 表达和激活 p53/p21 信号通路抑制结直肠癌细胞增殖。
Chin J Integr Med. 2024 Jun;30(6):515-524. doi: 10.1007/s11655-024-3709-5. Epub 2024 Jan 13.
6
Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models.片仔癀对 T 细胞介导的抗 B16-F10、MC38 和 Hep1-6 肿瘤模型抗肿瘤活性的免疫调节作用。
Chin J Integr Med. 2024 Apr;30(4):348-358. doi: 10.1007/s11655-023-3749-2. Epub 2024 Jan 12.
7
Pien Tze Huang alleviates Concanavalin A-induced autoimmune hepatitis by regulating intestinal microbiota and memory regulatory T cells.片仔癀通过调节肠道微生物群和记忆调节性 T 细胞缓解伴刀豆球蛋白 A 诱导的自身免疫性肝炎。
World J Gastroenterol. 2023 Dec 7;29(45):5988-6016. doi: 10.3748/wjg.v29.i45.5988.
8
National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data.中国 2005-20 年的癌症负担的国家和省级趋势:基于国家死亡率监测数据的分析。
Lancet Public Health. 2023 Dec;8(12):e943-e955. doi: 10.1016/S2468-2667(23)00211-6.
9
ANRIL promotes the regulation of colorectal cancer on lymphatic endothelial cells via VEGF-C and is the key target for Pien Tze Huang to inhibit cancer metastasis.抑癌基因 ANRIL 通过 VEGF-C 促进结直肠癌淋巴管内皮细胞的调控,是抑制癌症转移的关键靶点。
Cancer Gene Ther. 2023 Sep;30(9):1260-1273. doi: 10.1038/s41417-023-00635-w. Epub 2023 Jun 7.
10
Pien-Tze-Huang prevents hepatocellular carcinoma by inducing ferroptosis via inhibiting SLC7A11-GSH-GPX4 axis.片仔癀通过抑制SLC7A11-GSH-GPX4轴诱导铁死亡来预防肝细胞癌。
Cancer Cell Int. 2023 Jun 6;23(1):109. doi: 10.1186/s12935-023-02946-2.

传统中医药,特别是在肝癌治疗方面的前景与挑战。

Promise and challenges of traditional Chinese medicine, specifically , in liver cancer treatment.

机构信息

School of Medicine, Nankai University, Tianjin 300071, China.

Department of General Surgery, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100853, China.

出版信息

World J Gastroenterol. 2024 Oct 28;30(40):4380-4385. doi: 10.3748/wjg.v30.i40.4380.

DOI:10.3748/wjg.v30.i40.4380
PMID:39494098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11525868/
Abstract

Liver cancer, one of the most common malignancies worldwide, ranks sixth in incidence and third in mortality. Liver cancer treatment options are diverse, including surgical resection, liver transplantation, percutaneous ablation, transarterial chemoembolization, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and traditional Chinese medicine (TCM). A multidisciplinary team (MDT) is essential to customize treatment plans based on tumor staging, liver function, and performance status (PS), ensuring individualized patient care. Treatment decisions require a MDT to tailor strategies based on tumor staging, liver function, and PS, ensuring personalized care. The approval of new first-line and second-line drugs and the establishment of standard treatments based on immune checkpoint inhibitors have significantly expanded treatment options for advanced liver cancer, improving overall prognosis. However, many patients do not respond effectively to these treatments and ultimately succumb to the disease. Modern oncology treatments, while extending patient survival, often come with severe side effects, resistance, and damage to the body, negatively impacting quality of life. Huang 's study published at rigorously validates the anticancer properties of , enhancing our understanding of TCM and contributing to new liver cancer treatment strategies. For over 5000 years, TCM has been used in East Asian countries like China to treat various diseases, including liver conditions. Analysis of real-world clinical data suggests that for patients with advanced-stage tumors lacking effective treatments, integrated TCM therapies could provide significant breakthroughs.

摘要

肝癌是全球最常见的恶性肿瘤之一,发病率位居第六,死亡率位居第三。肝癌的治疗方法多种多样,包括手术切除、肝移植、经皮消融、经动脉化疗栓塞、放疗、化疗、靶向治疗、免疫治疗和中医药(TCM)。多学科团队(MDT)是根据肿瘤分期、肝功能和体能状态(PS)制定个体化治疗计划的关键,以确保患者得到个体化的护理。治疗决策需要 MDT 根据肿瘤分期、肝功能和 PS 来制定策略,以确保个性化的护理。新的一线和二线药物的批准以及基于免疫检查点抑制剂的标准治疗方案的建立,极大地扩展了晚期肝癌的治疗选择,改善了整体预后。然而,许多患者对这些治疗方法没有有效反应,最终还是死于该疾病。现代肿瘤学治疗虽然延长了患者的生存时间,但往往伴随着严重的副作用、耐药性和对身体的损害,对生活质量产生负面影响。Huang 的研究在严格的条件下验证了 的抗癌特性,增进了我们对 TCM 的理解,并为新的肝癌治疗策略提供了依据。5000 多年来,中医药一直在包括中国在内的东亚国家用于治疗各种疾病,包括肝脏疾病。对真实世界临床数据的分析表明,对于缺乏有效治疗方法的晚期肿瘤患者,综合中医药疗法可能会带来重大突破。